ILYX-002 / Iolyx Therap - LARVOL DELTA

ILYX-002 Pharmacokinetics in Healthy Volunteers (ANZCTR) - P1 | N=16 | Completed | Sponsor: Iolyx Australia Pty Ltd | Recruiting ➔ Completed

Trial completion • Dry Eye Disease • Ophthalmology

Phase 2 Trial Results of Topically Administered ILYX-002, a Novel Immune Modulator for Inflammatory Dry Eye Disease (ARVO 2025) - "ILYX-002 was considered safe and well tolerated, with early signs of efficacy that were sustained through the end of treatment. As researchers strive to develop innovative solutions, treatments like ILYX-002 hold promise for addressing the unmet medical needs in this patient population."

P2 data • Dry Eye Disease • Ocular Inflammation • Ophthalmology

Iolyx Therapeutics to Present at Multiple Upcoming Ophthalmology Conferences (GlobeNewswire) - "Iolyx Therapeutics...today announced acceptance of abstracts in four upcoming industry events, where the company will present new developments and updates on its lead candidate, ILYX-002, for immune-driven dry eye disease (DED) from a recent Phase 2 clinical trial, ILYX-002-201."

P2 data • Dry Eye Disease

A Trial of the Safety and Therapeutic Effects of ILYX-002 Versus Vehicle Control for Treatment of Dry-Eye Disease in Patients with Autoimmune Disease (ANZCTR) - P2 | N=110 | Completed | Sponsor: Iolyx Australia Pty Ltd. | Recruiting ➔ Completed

Trial completion • Dry Eye Disease • Immunology • Ophthalmology

ILYX-002 Pharmacokinetics in Healthy Volunteers (ANZCTR) - P1 | N=16 | Recruiting | Sponsor: Iolyx Australia Pty Ltd | Initiation date: Nov 2024

Trial initiation date • Dry Eye Disease • Ophthalmology

ILYX-002 Pharmacokinetics in Healthy Volunteers (ANZCTR) - P1 | N=16 | Recruiting | Sponsor: Iolyx Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Dry Eye Disease • Ophthalmology

ILYX-002 Pharmacokinetics in Healthy Volunteers (ANZCTR) - P1 | N=16 | Not yet recruiting | Sponsor: Iolyx Australia Pty Ltd

New P1 trial • Dry Eye Disease • Ophthalmology